You should consider shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Virgin Galactic Holdings Inc. (NYSE:SPCE) if you are looking for a great stocks to invest in. Starting with the RARE shares, which traded at $41.56 at the close of the recent session, gaining 6.18%. On Tuesday, the company’s shares shed $2.42 from its value which represented in intraday trading. The stock is now -22.56% lower in year-to-date (YTD) trading. RARE’s intraday high was $42.00 while its lowest price touched $39.60. The stock’s 52-week high price is $74.50, which means the current price is at -44.21%. In terms of trading activity, the daily trading volume rose to 1217603 against 200-day average trading volume of 547,922 shares.
What are analyst forecasts for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)?
At a consensus rating of 4.77, RARE is trending as a streaking Strong Buy, as it has been the case a month ago when 12 analysts called it a Strong Buy. Two months ago, 12 analysts recommended, on average, that RARE stock is a Strong Buy. The Healthcare company’s shares’ overall bullish trend saw it close lower on Tuesday compared to its opening price of $39.88 on the day.
Forecasts for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) give the stock a fair value for the growth of 44.59% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $75.00, which means the price per share could rise by nearly $33.44. The price range target is between a low of $45.00 and a high of $87.00. The stock would need to gain by about $52.23 to hit the estimated high or 0.85% from its 12-month low.
The consensus among 18 analysts is that it is a good time for one to Overweight in the Ultragenyx Pharmaceutical Inc. 13 analysts rate RARE as a Buy, with 0 of 18 analysts rate it as a Sell. 1 have valued the stock as Overweight and 4 have recommended that investors Hold.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Upgrades and Downgrades
In terms of rating changes, Wedbush on August 02, 2019, Resumed Ultragenyx Pharmaceutical Inc. (RARE) at Outperform. They believe the stock could reach $75 in the near term. Analysts at Morgan Stanley have assigned a Overweight rating for the stock in their research note on March 27, 2019 with an estimated price target of $83. Moreover, Raymond James analysts issued a rating of Outperform for the stock on February 22, 2019, giving it a price target of $80 for the next 12 months. On January 02, 2019, the stock earned a Mkt Perform rating due to an analyst call from Raymond James, while analysts from Citigroup on November 08, 2018 suggested that the stock is Neutral.
Virgin Galactic Holdings Inc. (NYSE:SPCE) adds $0.02 on Tuesday
The SPCE stock has tanked -25.40% year-to-date and is currently trading at $7.46, which is -42.30% below its 52-week high. The company shares gained 0.27% on the day and have risen nearly 8.12% off a low hit. At current levels, Virgin Galactic Holdings Inc. has a valuation of about $4.54M. As of 12/03/19, this stock has risen 3.32% during the week and closed at $7.44 in the previous session. However, recent Virgin Galactic Holdings Inc. stock performance shows that SPCE shares are -22.61% down over the last month, and -27.85% down for the last three months.
Sales Growth to climb 156.10% for the year
How well will Virgin Galactic Holdings Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $1.78M and $1.78M in current quarter sales. The consensus estimated for the current quarter is $1.78M from sales. Forecasts for this fiscal year are between $4M and $5.42M and the consensus estimate for sales is at $4.71M.
Who owns shares in Virgin Galactic Holdings Inc. (SPCE)?
Let’s briefly focus on the share ownership of the Virgin Galactic Holdings Inc. (NYSE:SPCE) stock, where we find that 17.32% of shares are held by institutions.